title: The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination.
abstract: Anti-tumor vaccination is being evaluated as a prophylactic and therapeutic strategy against cancer growth, dissemination (spreading) or recurrence. Although a large number of studies investigate in detail the identity of antigens to be used for efficacious immune intervention, there have been few studies investigating the optimal form for antigen to be used in the vaccine. Here we show in a mouse H-2(d) MHC background and for NY-ESO-1 that genetic (plasmid DNA) but not full length protein vaccine is capable of inducing a protective prophylactic anti-tumor cytotoxic T-cell immune response in vivo. Peptide vaccination using nominal MHC class I epitope adjuvanted with a Toll Like Receptor agonist such as stabilized RNA can also provide some anti-tumor protection. Our results highlight the idea that when evaluating the clinical efficacy of a cancer vaccine, not only the identity of the antigen but also the format of the vaccine is of the utmost importance.
authors.affiliation: University Hospital of Zürich, Department of Oncology, Häldeliweg 4, 8044 Zürich, Switzerland.
authors.forename: Iana
authors.initials: I
authors.lastname: Parvanova
authors.forename: Lorna
authors.initials: L
authors.lastname: Rettig
authors.forename: Alexander
authors.initials: A
authors.lastname: Knuth
authors.forename: Steve
authors.initials: S
authors.lastname: Pascolo
mesh_terms: D000818:Animals; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology; D018398:Homeodomain Proteins / Q000235:genetics*; D007167:Immunotherapy / Q000379:methods; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000517:prevention & control* / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D016896:Treatment Outcome; D014611:Vaccination / Q000379:methods; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000276:immunology; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; C512201:Eso-1 protein, mouse; D000949:Histocompatibility Antigens Class II; D018398:Homeodomain Proteins; D019444:Vaccines, DNA; D022223:Vaccines, Subunit